NEW YORK (AP) -- Biotechnology company ImmunoGen Inc. said Friday it has signed a 5 million euro ($6.8 million) manufacturing contract with pharmaceutical maker Sicor Italy to purchase cell-killing agents for cancer therapies. The agents are used to produce an ImmunoGen technology that is designed to kill cancer cells while minimizing damage to healthy tissue.
